This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Mechanism of development of type III hyperlipidaemia

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • usually type III hyperlipidaemia occurs as a result of an autosomal recessively inherited condition (with variable penetrance)
    • there is impaired binding of apoE to its receptor
      • as a result of a mutation of polymorphism of the apo E gene
      • most common mutation is polymorphism, apo E2 (cysteine is substituted for arginine at position 158) - in 90% of cases of type III hyperlipidaemia patients are homozygous for apo E2
      • apo E2 homozygosity may not, in itself, cause hyperlipoprolipoproteinaemia (apo E2 homozygosity occurs in about 1% of population) - another condition that results in an additional catabolic effect or overproduction of VLDL may be required. This explains why type III hyperlipidaemia may be associated with conditions such as diabetes or hypothyroidism. Other possible circumstances where type III hyperlipidaemia may develop with apo E2 homozygosity include co-inheritance of a polygenic tendency to hypertriglyceridaemia, high alcohol intake and obesity
      • other mutations of apo E have been described including an apo E deficiency; also a mutation of the apo E receptor-binding domain have been described which results in type III hyperlipidaemia in heterozygote

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.